Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Duration of anticoagulant effect in relation to urinary excretion of dextran sulphate.

Literature DB >> 13364377

Duration of anticoagulant effect in relation to urinary excretion of dextran sulphate.

S M JEAVONS, C R RICKETTS, K W WALTON.

Abstract

Entities: Chemical

Keywords: DEXTRAN/therapeutic use; THROMBOEMBOLISM/therapy

Mesh：

Substances：

Year: 1956 PMID： 13364377 PMCID： PMC2035677 DOI： 10.1136/bmj.2.5000.1016

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

× No keyword cloud information.

26 in total

1. Dextran sulphate: use as an anticoagulant, and action in lowering serum cholesterol.

Authors: H COHEN; G R TUDHOPE
Journal: Br Med J Date: 1956-11-03

2. The effect of dextran sulphate injections on serum lipoproteins.

Authors: S M JEAVONS; C R RICKETTS
Journal: J Clin Pathol Date: 1956-08 Impact factor: 3.411

3. Alopecia and other toxic effects of heparin and synthetic heparinoids.

Authors: J S HIRSCHBOECK; F W MADISON; A V PISCIOTTA
Journal: Am J Med Sci Date: 1954-03 Impact factor: 2.378

4. Therapeutic trial of the synthetic heparin analogue dextran sulphate.

Authors: C R RICKETTS; K W WALTON; B D VAN LEUVEN; A BIRBECK; A BROWN; A C KENNEDY; C C BURT
Journal: Lancet Date: 1953-11-14 Impact factor: 79.321

5. Observations on the effects, of a series of dextran sulphates of varying molecular weight on the formed elements of the blood in vitro.

Authors: K W WALTON
Journal: Br J Pharmacol Chemother Date: 1953-09

6. The metachromatic activity of urine following the injection of heparin.

Authors: L B JAQUES; E NAPKE; S W LEVY
Journal: Circ Res Date: 1953-07 Impact factor: 17.367

7. The dynamic equilibrium between circulating and extravascular plasma proteins.

Authors: D GITLIN; C A JANEWAY
Journal: Science Date: 1953-09-11 Impact factor: 47.728

8. [Falling of hair after anticoagulant therapy].

Authors: R FISCHER; J BIRCHER; T REICH
Journal: Schweiz Med Wochenschr Date: 1953-05-30

9. The turnover rate of serum albumin in man as measured by I131-tagged albumin.

Authors: K STERLING
Journal: J Clin Invest Date: 1951-11 Impact factor: 14.808

10. The use of sulphated whole blood in the assay of heparin.

Authors: S S ADAMS
Journal: J Pharm Pharmacol Date: 1950-11 Impact factor: 3.765

8 in total

1. The estimation and recovery of dextran sulphates in biological fluids.

Authors: H A ELLIS; K W WALTON
Journal: J Clin Pathol Date: 1959-09 Impact factor: 3.411

2. The amyotonia congenita syndrome.

Authors: J N WALTON
Journal: Proc R Soc Med Date: 1957-05

3. Alopecia following treatment with dextran sulphate and other anticoagulant drugs.

Authors: G R TUDHOPE; H COHEN; R W MEIKLE
Journal: Br Med J Date: 1958-05-03

4. Dissociation as a guide to developmental assessment.

Authors: R S ILLINGWORTH
Journal: Arch Dis Child Date: 1958-04 Impact factor: 3.791

5. Benign congenital myopathy with myasthenic features.

Authors: N GESCHWIND; J A SIMPSON; J N WALTON
Journal: J Neurol Neurosurg Psychiatry Date: 1956-08 Impact factor: 10.154

6. ANNOTATIONS.

Authors:
Journal: Br Med J Date: 1956-11-17

7. Dextran Sulfate as a Substitute for Heparin.

Authors:
Journal: Can Med Assoc J Date: 1957-01-15 Impact factor: 8.262

8. The effects of heparin and dextran sulphate on cultured mouse limb bones.

Authors: H A Ellis; K M Peart
Journal: Br J Exp Pathol Date: 1970-02

8 in total